Stereotaxis, Inc. (STXS), a surgical robotics company for minimally invasive endovascular interventions, announced on Thursday that it has received its first firm order for its next-generation robotic system, GenesisX.
The order, placed by a pioneering European hospital, marks a critical milestone as the company prepares for the full commercial launch of GenesisX.
This innovative robotic system enhances accessibility to Robotic Magnetic Navigation technology, which will be transformative for endovascular surgery.
GenesisX features a compact design with smaller magnets and integrated magnetic shielding, offering significant improvements in speed, responsiveness, and workflow.
It also operates with standard 120/230V power outlets and requires no structural anchoring, making it easier to implement in clinical settings.
With CE Mark already obtained in Europe and FDA submission underway, Stereotaxis plans to expand its portfolio of compatible catheters and achieve additional regulatory approvals in both Europe and the U.S. throughout 2025.
Stereotaxis is set to revolutionize the field of minimally invasive surgery, and this first order for GenesisX marks an important step in advancing robotic adoption in the operating room.
Currently, STXS is trading at $2.35 up by 4.86%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.